Company Reports

DSM-Firmenich is one of the largest consumer chemical companies in the world. A majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

DSM-Firmenich reported organic sales growth accelerating to 6% in the second quarter, outpacing its own full-year guidance and Vara-compiled consensus. EBITDA margin also saw a slight increase. Shares rose about 13% on July 30.

DSM-Firmenich reported 4% organic sales growth in the first quarter, driven entirely by volume across all segments. The company announced a dual listing on the SIX Swiss Exchange from May 21 and a EUR 540 million share buyback. Shares rose by about 7% on May 6.

DSM-Firmenich reported 2% organic sales growth in the fourth quarter on a comparable basis, incorporating the announced divestment of its animal nutrition and health division. The company did not provide guidance for 2026, which contributed to an 8% share price decline on Feb. 12 amid uncertainty.

DSM-Firmenich is one of the largest consumer chemical companies in the world. A majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

DSM-Firmenich reported a slowdown in third-quarter organic sales growth to 2% due to more cautious customer behavior. Full-year EBITDA guidance was lowered by EUR 100 million to EUR 2.3 billion, reflecting a larger currency headwind and a weaker-than-expected improvement in vitamins.

DSM-Firmenich is one of the largest consumer chemical companies in the world. A majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

DSM-Firmenich reported first-half 2025 organic sales growth of 7% and EBITDA of EUR 1,260 million, 29% higher than the prior year. The results align with the company-compiled consensus, and management confirmed the full-year guidance.

DSM-Firmenich is one of the largest consumer chemical companies in the world. A majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

DSM-Firmenich reported first-quarter 2025 organic sales growth of 8% and EBITDA of EUR 650 million, 40% higher than the prior year. The results include a one-off positive price impact from the vitamin supply disruption. The full-year guidance was confirmed.

Ingredient producer shares initially showed resilience following the tariff news on April 2 because it had limited direct impact on them. However, they were swept up in the market turbulence and corrected by a mid- to high-single digit on April 7 as investors began to digest the implications.

DSM-Firmenich delivered 2024 adjusted EBITDA of EUR 2.1 billion, in line with guidance. On Feb. 11, the company also announced the sale of its stake in the feed enzyme alliance to its partner Novonesis for EUR 1.5 billion.

DSM-Firmenich reported solid third-quarter earnings and upgraded the 2024 adjusted EBITDA guidance by 5% to EUR 2.1 billion, citing a one-off tailwind in the vitamins market.

Wide-moat DSM-Firmenich delivered organic sales growth of 7% in the second quarter of 2024, substantially ahead of 4% Vara consensus. Growth accelerated for the perfumery and beauty segment and the taste, texture and health business and turned positive for both the health, nutrition and care as well as the animal nutrition and health segments. The adjusted EBITDA margin of 15.9% was 240 basis points ahead of the same period last year and represented a sequential improvement of 80 basis points compared with the first quarter. The sequential improvement was primarily the result of higher profitability for animal nutrition and health with a EUR 20 million contribution (2.5% of segment sales) from the vitamin transformation plan and cost synergies. For the full year, DSM-Firmenich expects a EUR 200 million EBITDA contribution from synergies and the vitamin transformation program. Given solid momentum across the business, management upgraded full-year 2024 EBITDA guidance to around EUR 2 billion from at least EUR 1.9 billion previously. This aligns with our forecast and we confirm our EUR 130 fair value estimate. Shares were up around 5% in intraday trading following the consensus beat, but still offer upside of around 12%.

We confirm our EUR 130 fair value estimate for wide-moat DSM-Firmenich after it reported first-quarter 2024 adjusted EBITDA of EUR 463 million, in line with the Vara consensus. This represents an 11% decrease compared with the same period last year, which was mainly attributed to ongoing challenging market conditions in vitamins. Still, management indicated that market momentum is improving and confirmed full-year EBITDA guidance of at least EUR 1.9 billion, which is broadly aligned with our forecast of full-year adjusted EBITDA of around EUR 2 billion.

DSM-Firmenich is one of the largest consumer chemical companies in the world. A majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

Wide-moat DSM-Firmenich reported 2023 annual results with adjusted EBITDA of EUR 1.8 billion, in line with company-compiled consensus, our estimates and guidance. The highlight of the update was the announcement of plans to separate the animal nutrition and health business from the group, slated for 2025. Although we didn’t expect this announcement so soon after the completion of the merger, we believe this is the logical next step for DSM-Firmenich, considering the commoditized nature of the ANH business and the substantial toll that animal feed-grade vitamins have taken on earnings in recent quarters. The move will reduce earnings volatility and decrease capital intensity, allowing DSM-Firmenich to become fully focused on defensive consumer end markets. We view the decision as positive for our moat rating and Morningstar Uncertainty Rating, likely to result in a multiple rerating. Unsurprisingly, investors welcomed the news, sending shares around 14% higher in intraday trading. Although we will tweak our short-term estimates downward to reflect prolonged angst in the vitamins market weighing on 2024 profit, we don’t expect to make a material change to our EUR 135 fair value estimate as the Feb. 15 announcement has instilled more confidence in our long-term forecast and management’s commitment to maximize shareholder value. Despite the Feb. 15 run-up in price, we believe the current share price still offers substantial upside of around 30% for patient investors.

Wide-moat DSM-Firmenich reported third-quarter adjusted EBITDA of EUR 409 million, roughly in line with the EUR 405 million company-compiled consensus. Trading conditions remain difficult across vitamin end markets, with no signs of abating in the fourth quarter. This caused management to narrow its full-year adjusted EBITDA guidance to EUR 1.8 billion, the lower end of its prior EUR 1.8 billion-EUR 1.9 billion range. It revised the negative impact from the vitamins business to EUR 500 million for the year from EUR 400 million. Despite the more negative outlook, the market reacted positively to DSM-Firmenich’s update, sending shares around 7% higher at the time of writing. We believe this is due to an improvement in cash conversion in the quarter thanks to increased management focus, as well as to more clarity provided around longer-term plans to restore vitamins profitability and drive cost and revenue synergies following the merger. We lowered our fair value estimate to EUR 135 per share from EUR 140 after incorporating the short-term EBITDA headwinds (our forecast was at the upper end of the prior range). Our long-term forecast is unchanged, with EBITDA margin expected to reach 23% by 2032 and revenue growth just shy of 5% on average between 2024 and 2032. We believe the shares still offer plenty of appreciation potential for patient investors, trading in 5-star territory.

DSM-Firmenich is one of the largest consumer chemical companies in the world. Following the merger of Firmenich and DSM, a majority of revenue is derived from segments that benefit from leading market positions across increasingly consolidated industries, such as flavor and fragrance, and the broader food ingredients market. This has earned the company a wide moat, stemming from intangible assets and switching costs.

Wide-moat DSM-Firmenich’s first-half 2023 results delivered few surprises, having been largely revealed as part of a trading update at the end of June. Pro forma adjusted EBITDA amounted to EUR 929 million, in line with the company-compiled consensus and our forecast. Still, this represents a decline of 21% compared with the same period last year and translates to an EBITDA margin of 15.1%—300 basis points lower than the first half last year and significantly below the company’s midterm target of 22% to 23%. As previously announced, the lower profitability was primarily the result of cyclically weak conditions in the vitamins market that affected the commoditized animal nutrition and health segment, and to a lesser extent the health, nutrition, and care segment. Management confirmed the guidance it issued at the end of June for full-year EBITDA of EUR 1.8 billion to EUR 1.9 billion.